Results 21 to 30 of about 4,251 (181)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor [PDF]

Journal of Hematology & Oncology, 2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic ...
Jingjing Wu, Mingzhi Zhang, Delong Liu
doaj   +2 more sources

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study. [PDF]

Cancer Med
In a real‐world matched cohort study of treatment‐naïve TP53 wild‐type CLL patients, venetoclax plus obinutuzumab demonstrated significantly longer time to next treatment and improved 4‐year overall survival compared to first‐line acalabrutinib. Despite higher rates of cytopenias and infections, the venetoclax‐based regimen showed superior efficacy ...
Liao PW, Ko BS, Su YC, Chao WT, Teng CJ.
europepmc   +2 more sources

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives. [PDF]

Eur J Haematol
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gaidano G, Danesi R.
europepmc   +2 more sources

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Abstract Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL.
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.   +13 more
europepmc   +2 more sources

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [PDF]

, 2016
Background Irreversible inhibition of Bruton\u27s tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).
Jones, J. A., Harrington, B., Devereux, S., Furman, R. R., Chaves, J., Byrd, J. C., O\u27Brien, S., +20 additional authors, Wierda, W. G., Barrientos, J. C., Schuh, A.   +10 more
core   +3 more sources

The acalabrutinib-bound BTK kinase domain.

, 2023
a. Overall structure of the BTK KD/acalabrutinib complex. Key features of the kinase domain are labeled. Acalabrutinib is shown in yellow sticks and covalently attached to Cys481. Activation loop is colored red with Tyr551 shown in sticks.
Amy H. Andreotti (366314), David Y. Lin (16913868)   +1 more
core   +1 more source

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial [PDF]

, 2021
PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
Rothbaum, Wayne, Pinilla-Ibarz, J, Seymour, John F., Byrd, John C, Garcia-Marco, JA, Robak, Tadeusz, Lepretre, S, Furman, RR, Furman, Richard R., Seymour, JF, Jurczak, W, Kay, Neil, O'Brien, Susan, Sohoni, S, Ghia, P, Patel, Priti, Nuri Yenerel, M, Garcia-Marco, Jose A., Byrd, John C., Izumi, Raquel, Kater, Arnon P, Stilgenbauer, S, Izumi, R, Kay, N, Kater, Arnon P., Robak, T, Pinilla-Ibarz, Javier, Lepretre, Stephane, Stilgenbauer, Stephan, Jurczak, Wojciech, Higgins, K, Mato, Anthony, Illés, A, Furman, Richard R, Chanan-Khan, A, Hillmen, Peter, Rothbaum, W, O’Brien, S, Illés, Arpad, Higgins, Kara, Mato, A, Sohoni, Sophia, Yenerel, Mustafa Nuri, Byrd, JC, Kater, AP, Hamdy, A, Garcia-Marco, Jose A, Hamdy, Ahmed, Hillmen, P, Seymour, John F, Ghia, Paolo, Chanan-Khan, Asher, Patel, P   +52 more
core   +1 more source

Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)

eJHaem, 2021
Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks
Thura W. Htut, Myat M. Han, Kyaw Z. Thein   +2 more
doaj   +1 more source

FRAILTY ASSESSMENT AS PREDICTOR OF BLEEDING FOR PATIENTS TREATED WITH ACALABRUTINIB

Hematology, Transfusion and Cell Therapy, 2023
Introduction: The American Society of Clinical Oncology (ASCO) promotes the routine use of a comprehensive geriatric assessment, particularly emphasizing frailty, to identify vulnerabilities not detected in the standard clinical evaluation.
TX Carneiro, JLS Sales, JS Tavares, IJM Wanderley, JKD Santos, LBC Leão, LDS Pimentel, NS Moraes   +7 more
doaj   +1 more source

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Therapeutic Advances in Hematology, 2023
Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical ...
Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Jeffrey R. Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Talha Munir   +13 more
doaj   +1 more source